Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 2 (2)
P 3 (1)

Trial Status

Active Not Recruiting2
Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT02314169Phase 2Active Not Recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

NCT04444921Phase 3Active Not Recruiting

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

NCT04221893Not ApplicableRecruiting

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT03439085Phase 2Terminated

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Showing all 4 trials

Research Network

Activity Timeline